Skip to content

Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science

Study of Same TCM Syndrome for Different Diseases and Same Treatment for Different Diseases of Primary Hepatocellular Carcinoma and Colorectal Cancer Under the Perspective of System Science

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03189992
Enrollment
320
Registered
2017-06-16
Start date
2014-01-31
Completion date
2018-12-31
Last updated
2017-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Tumor of Small Intestine Metastatic to Liver

Brief summary

Traditional Chinese medicine (TCM) syndrome is a core foundation of disease knowledge, clinical diagnosis and treatment and curative effect evaluation in TCM. Same TCM Syndrome for Different Diseases and Same Treatment for Different Diseases is one of the characteristics of TCM syndrome differentiation and treatment. This study is the TCM disease syndrome combination research baced on principles and methods of system biology, which is through acquisition of primary hepatocellular carcinoma (HCC) and colorectal cancer patients with TCM syndrome information, detection of clinical indicators and genomic, proteomic, and metabolites changes, analyzing the correlation between TCM syndromes and biological information, and revealing its biological material characteristics and the molecular mechanisms of Same TCM Syndrome for Different Diseases;Developing and implementing the program of TCM syndrome differentiation and treatment for HCC and colorectal cancer to evaluate the efficacy of TCM syndrome based-treatment of HCC and colorectal cancer with TCM syndrom scores, clinical and systems biological indicators, quality of life and survival rate, and to revealing the mechanism of the Same Treatment for Different Diseases.

Detailed description

Traditional Chinese medicine (TCM) syndrome is a core foundation of disease knowledge, clinical diagnosis and treatment and curative effect evaluation in TCM. Same TCM Syndrome for Different Diseases and Same Treatment for Different Diseases is one of the characteristics of TCM syndrome differentiation and treatment. In this study, the investigators adopted the transcriptome analysis, proteome analysis and metabolic diversity analysis of the patients with different syndromes of liver cancer and colorectal cancer, and integrate omics information, combining macro and micro methods to screen biomarkers of syndromes

Interventions

DRUGBushen-Jianpi Dedoction

A traditional chinese medicine prescription

DRUGcinobufotalin injection

an effective Chinese preparation to treat malignant tumor.

Sponsors

Shanghai University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of primary liver cancer (HCC) and colorectal cancer after surgery. 2. Liver cancer and colorectal cancer liver and kidney yin deficiency and spleen qi deficiency syndrome diagnosis standard : Yin deficiency of liver and kidney and spleen qi deficiency syndrome see hypochondriac pain, waist and knee Limp, fever, night sweats, dry mouth and throat, fatigue, anorexia, abdominal distension after eating more, red or pale tongue, less moss or Light peel, pulse fine.

Exclusion criteria

(1) there is a serious heart, kidney, and other diseases of the hematopoietic system effect of drug evaluation factors; (2)Mental disorders (3)Digestive tract obstruction; (4) poor compliance.

Design outcomes

Primary

MeasureTime frameDescription
Complete patient recruitment24 monthsComplete transcriptome microarray detection

Countries

China

Contacts

Primary Contactshi bing su, Professor
shibingsu07@163.com021-51323013

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026